Renal biopsy in children with IgA vasculitis

Abstract Introduction Henoch-Schönlein purpura nephritis (HSN) is defined as Henoch-Schönlein purpura with kidney involvement, including hematuria and/or proteinuria. The aim of this study was to evaluate the data of HSN patients who underwent renal biopsy, and compare the main clinical and laboratory parameters that may affect renal biopsy findings, treatment protocols, and short- and long-term outcome of those patients. Methods Biopsies performed in 72 HSN patients between January 2007 to January 2017 were retrospectively evaluated. They were divided into two groups according to renal biopsy classification of the International Study of Kidney Disease in Children. Renal outcome, clinical and laboratory parameters, treatment protocols, and outcome were compared between groups. Short- and long-term follow-up of patients were evaluated. Results Of 72 patients, 47 were male (65.3%) and 44 (61.1%) were ≤10 years of age. Neutrophil-lymphocyte ratio was found higher in patients with scrotal involvement (p=0.042). Short-term unfavorable outcome was significantly higher in patients with scrotal involvement (p=0.038). Patients with hypertension and decreased creatinine clearance were found to have more unfavorable outcomes in long-term follow-up (p=0.029, p=0.040). Conclusion Cyclosporin-A and cyclophosphamide could be effective in steroid unresponsive HSN patients. Patients with scrotal involvement, decreased creatinine clearance, and hypertension should be closely monitored for sequelae of HSN.

[1]  H. Yakut,et al.  Predictive role of neutrophil to lymphocyte ratio and mean platelet volume in Henoch-Schönlein purpura related gastrointestinal and renal involvement. , 2020, Archivos argentinos de pediatria.

[2]  S. Ozen,et al.  Different histological classifications for Henoch-Schönlein purpura nephritis: which one should be used? , 2019, Pediatric Rheumatology.

[3]  C. Zeng,et al.  Renal Prognosis and Related Risk Factors for Henoch-Schönlein Purpura Nephritis: A Chinese Adult Patient Cohort , 2018, Scientific Reports.

[4]  C. Silva,et al.  Henoch-Schönlein purpura nephritis: initial risk factors and outcomes in a Latin American tertiary center , 2018, Clinical Rheumatology.

[5]  Gaofeng Zhang,et al.  Risk Factors Associated with Renal Involvement in Childhood Henoch-Schönlein Purpura: A Meta-Analysis , 2016, PloS one.

[6]  T. Moore,et al.  Azathioprine therapy for steroid-resistant Henoch-Schönlein purpura: a report of 6 cases , 2016, Pediatric Rheumatology.

[7]  Z. Ekinci,et al.  Is neutrophil-to-lymphocyte ratio valid to predict organ involvement in Henoch–Schönlein purpura? , 2016, Rheumatology International.

[8]  Q. Ma,et al.  Henoch-Schönlein purpura with joint involvement: Analysis of 71 cases , 2016, Pediatric Rheumatology.

[9]  T. Ting.  Diagnosis and management of cutaneous vasculitis in children. , 2014, Pediatric clinics of North America.

[10]  M. Duman,et al.  The relationship of neutrophil-to-lymphocyte ratio with gastrointestinal bleeding in Henoch–Schonlein purpura , 2014, Rheumatology International.

[11]  Jean-Claude Davin,et al.  Henoch-Schönlein purpura nephritis: an update , 2001, European Journal of Pediatrics.

[12]  K. Sugita,et al.  Methylprednisolone pulse therapy and intravenous cyclophosphamide therapy combined with cocktail therapy in severe pediatric Henoch-Schönlein purpura nephritis patient , 2013, CEN Case Reports.

[13]  Y. Tabel,et al.  Clinical features of children with Henoch-Schonlein purpura: risk factors associated with renal involvement. , 2012, Iranian journal of kidney diseases.

[14]  Yue Du,et al.  Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil , 2012, Pediatric Nephrology.

[15]  Y. Kawasaki.  The pathogenesis and treatment of pediatric Henoch–Schönlein purpura nephritis , 2011, Clinical and Experimental Nephrology.

[16]  T. Jahnukainen,et al.  Cyclosporine A vs. methylprednisolone for Henoch–Schönlein nephritis: a randomized trial , 2011, Pediatric Nephrology.

[17]  H. Yim,et al.  Cyclosporin A therapy for Henoch–Schönlein nephritis with nephrotic-range proteinuria , 2011, Pediatric Nephrology.

[18]  T. Jahnukainen,et al.  Renal manifestations of Henoch–Schönlein purpura in a 6-month prospective study of 223 children , 2010, Archives of Disease in Childhood.

[19]  A. Bakkaloğlu,et al.  EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria , 2010, Annals of the rheumatic diseases.

[20]  A. Elmacı,et al.  Henoch Schonlein purpura in childhood: clinical analysis of 254 cases over a 3-year period , 2008, Clinical Rheumatology.

[21]  F. Sonmez,et al.  Clinical outcome in children with Henoch-Schönlein nephritis , 2007, Pediatric Nephrology.

[22]  F. Locatelli,et al.  Predictors of outcome in Henoch-Schönlein nephritis in children and adults. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  M. Çakır,et al.  Henoch-Schönlein purpura in north-eastern Turkey , 2006, Annals of tropical paediatrics.

[24]  Y. Kawasaki,et al.  Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  M. Candelli,et al.  Predictive factors of renal involvement or relapsing disease in children with Henoch-Schönlein purpura , 2004, Rheumatology International.

[26]  Y. Kawasaki,et al.  Clinical and pathological features of children with Henoch-Schoenlein purpura nephritis: risk factors associated with poor prognosis. , 2003, Clinical nephrology.

[27]  M. Nuutinen,et al.  Cyclosporin A for the treatment of severe Henoch-Schönlein glomerulonephritis , 2003, Pediatric Nephrology.

[28]  T. Jahnukainen,et al.  Outcome of Henoch-Schoenlein nephritis with nephrotic-range proteinuria. , 2003, Clinical nephrology.

[29]  E. Ito,et al.  Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis , 2003, Pediatric Nephrology.

[30]  E. Thervet,et al.  Henoch-Schönlein Purpura in adults: outcome and prognostic factors. , 2002, Journal of the American Society of Nephrology : JASN.

[31]  F. Saulsbury.  Epidemiology of Henoch-Schönlein purpura. , 2002, Cleveland Clinic journal of medicine.

[32]  Y. Ogawa,et al.  Risk factors of renal involvement and significant proteinuria in Henoch-Schönlein purpura , 2002, European Journal of Pediatrics.

[33]  J. Llorca,et al.  Henoch-Schönlein Purpura in Children from Northwestern Spain: A 20-Year Epidemiologic and Clinical Study , 2001, Medicine.

[34]  L. Brion,et al.  The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. , 1987, Pediatric clinics of North America.

[35]  J. Rapola,et al.  Henoch-Schönlein nephritis: long-term prognosis of unselected patients. , 1981, Archives of disease in childhood.

[36]  J B Stokes,et al.  The national high blood pressure education program. , 1974, Journal of the American Pharmaceutical Association.

[37]  S. R. Meadow,et al.  Schönlein-Henoch nephritis. , 1972, The Quarterly journal of medicine.

[38]  G. Striker,et al.  The nephritis of Henoch-Schönlein purpura. , 1973, Perspectives in nephrology and hypertension.